Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam Afdhal

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
Gastroenterology|September 28, 2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label studyMichael P Curry, Xavier Forns, Raymond T Chung, et al.
Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
Hepatology Communications|June 18, 2021
A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver DiseaseFredrik Åberg, Christopher J Danford, Maja Thiele, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
Gastroenterology|September 28, 2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label studyMichael P Curry, Xavier Forns, Raymond T Chung, et al.
Digestive Diseases and Sciences|May 1, 2012
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infectionPaul J Clark, Alexander J Thompson, Qianqian Zhu, et al.
Hepatology Communications|June 18, 2021
A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver DiseaseFredrik Åberg, Christopher J Danford, Maja Thiele, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 8